Aralez is created through the merger of POZEN Inc. and Tribute Pharmaceuticals Canada, and will be a world class special pharmaceutical company. Aralez has a proven senior management team with a diverse product portfolio of commercial assets, the anticipated launch of YOSPRALA®, and a strong balance sheet to fund additional growth opportunities.